High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Our data indicate that patients with plaque psoriasis prescribed apremilast in UK clinical practice have a high comorbidity burden and long-term, moderate-to-severe disease with special-site involvement, uncontrolled by systemic therapy, and which had a large detrimental impact on their QoL. These data highlight the need for timely treatment with appropriate therapy following diagnosis.
Authors
- Vaiva Gerasimaviciute (ORCID: https://orcid.org/0000-0001-8569-5849)
- Kave Shams (ORCID: https://orcid.org/0000-0002-8145-5351)
- David Neasham (ORCID: https://orcid.org/0000-0002-0270-0372)
- Andrew W. Taylor (ORCID: https://orcid.org/0000-0002-0330-8591)
- Myriam Cordey (ORCID: https://orcid.org/0009-0004-1797-0510)
- Anouchka Seesaghur (ORCID: https://orcid.org/0000-0003-2997-5867)
- Kathy Tran (ORCID: https://orcid.org/0009-0005-4421-1533)
- Jennifer Montgomery
- J. E. Morley (ORCID: https://orcid.org/0000-0003-2677-9027)
Institutions
- University of Leeds (GB)
- Amgen (United States) (US)
- Chapel Allerton Hospital (GB)
- Amgen (United Kingdom) (GB)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1007/s13555-025-01358-6
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00